Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2025 Aug 14;19(8):e0013411. doi: 10.1371/journal.pntd.0013411

Knowledge and attitude of populations on blackflies and onchocerciasis and participation in mass drug administration in first-line communities near Erin-Ijesha and Arinta waterfalls, Southwest Nigeria

Oluwadamilare Ganiu Dauda 1,*, Akinlabi Mohammed Rufai 1, Olabanji Ahmed Surakat 1, Oluwatoyin Adeola Oyeniran 2, Olusegun Quadri Adeshina 1, Abuh Ojomona Oboro 1, Azeezat Ayanbukola Ayannibi 3, Rhidollah Folashade Oyewusi 1, Glory Blessing Jokanola 1, Kamilu Ayo Fasasi 1, Monsuru Adebayo Adeleke 1
Editor: Nigel Beebe4
PMCID: PMC12367129  PMID: 40811731

Abstract

Background

Preliminary assessments have identified blackfly biting activity at Erin-Ijesha and Arinta waterfalls in Southwest Nigeria, predisposing first-line communities to a high risk of onchocerciasis. There is a need to assess knowledge of blackflies, onchocerciasis, and participation in treatment programs among residents of first-line communities near the waterfalls to evaluate onchocerciasis transmission risk.

Methods

A cross-sectional survey was conducted among 236 residents at Erin-Ijesha and Ipole-Iloro, two first-line communities using structured questionnaires. Data were entered into Microsoft Excel and analyzed using the Statistical Package for the Social Sciences (SPSS) software version 21. Relationships between variables were analyzed using t-test and chi-square, with a 95% confidence interval.

Results

Majority (73.3%) in Erin-Ijesha and (83.7%) in Ipole-Iloro reported knowledge of blackflies, with 83.3% and 87.0% aware of onchocerciasis, respectively. The majority of participants had no knowledge of how onchocerciasis is transmitted, with only 8.7% and 10.5% in Erin-Ijesha and Ipole-Iloro, respectively, linking the disease to blackfly bites. Ivermectin uptake was relatively high at 75.7% and 76.7% in Erin-Ijesha and Ipole-Iloro, respectively. Willingness to participate in future treatment programs was lower, at 64.7% and 64.0% in Erin-Ijesha and Ipole-Iloro, respectively. Level of education significantly influenced willingness to participate in future mass distribution of ivermectin (p < 0.05).

Conclusion

The limited understanding of blackfly bioecology and onchocerciasis among residents may lead to increased exposure to bites, thereby raising the risk of transmission. To address this, the federal and state ministries of health, along with treatment implementing partners, should enhance sensitization efforts and public health education during the annual Mass Drug Administration campaigns. Improving knowledge in these high-risk communities will encourage residents to take preventive measures against bites and improve treatment uptake, ultimately reducing the risk of disease transmission.

Author summary

Preliminary assessments have identified blackfly biting activity at Erin-Ijesha and Arinta waterfalls in Southwest Nigeria, predisposing first-line communities to a high risk of onchocerciasis. These blackflies make use of fast flowing rivers for the development of their immature stages and the adult fly transmits the parasite Onchocerca volvulus that causes severe skin and eye disorder. The disease is particularly prevalent in communities near suitable river systems. Erin-Ijesha and Ipole-Iloro, two first-line communities near the waterfalls, have been involved in mass ivermectin distribution programs for years. However, this study reveals a striking lack of knowledge among residents regarding the bioecology of blackflies, severity of onchocerciasis and the importance of ivermectin uptake. This knowledge gap has contributed to suboptimal treatment coverage, with some individuals refusing to participate in annual mass drug distribution. Given the high-risk status of these communities, these findings highlight the urgent need for the federal and state ministries of health and the NTD implementing partners to intensify on community sensitization efforts before and during mass drug administration campaigns to address misconceptions, improve public health awareness and optimize treatment program outcomes.

Introduction

Onchocerciasis is a skin disfiguring and blinding tropical infectious disease that significantly impacts affected communities and caused by the filarial nematode Onchocerca volvulus and transmitted by Simulium vector [1]. The epidemiology of onchocerciasis is influenced by the abundance, biting behaviour and vectorial capacity of local blackfly populations. The disease is found in isolated regions of Latin America and Yemen but the overwhelming majority of the global burden of onchocerciasis is concentrated in Africa, with more than 99% of cases occurring in 31 countries within sub-Saharan Africa [1]. Nigeria holds the highest global burden of onchocerciasis, accounting for approximately 40% of all cases worldwide [2,3]. The disease manifests through skin lesions accompanied by intense itching, as well as severe eye damage that can lead to blindness [1,4]. It is actually the second leading cause of preventable blindness in the world behind trachoma [5].

In Africa, onchocerciasis intervention programs shifted their goal from merely managing the disease as a public health issue by achieving a reduction in skin and ocular complications to targeting the elimination of the disease [6]. This change was driven by evidence from several studies demonstrating that O. volvulus elimination is achievable through community-directed ivermectin treatment (CDTI) [79]. Based on this evidence, disease control efforts in Nigeria have also primarily focused on mass drug administration (MDA) with ivermectin, a strategy that has been implemented for nearly 20 years, with states progressing at varying stages toward elimination [2]. This approach is crucial as it empowers endemic communities to decide the timing of drug distribution, choose their distributors, determine the distribution method, and take part in supervising mass drug administration [6]. Currently, ivermectin has been administered to over 34 million Nigerians achieving 80.6% geographical coverage [10].

A preliminary survey of rivers in Southwest Nigeria revealed blackfly activity at two major tourist sites, the Erin-Ijesha and Arinta waterfalls in Osun and Ekiti States, respectively, where such biting activity had not been previously reported or documented. Both states were classified as mesoendemic for onchocerciasis based on several surveys using the Rapid Epidemiological Mapping of Onchocerciasis (REMO) mapping conducted in 1995–1996 [2] and have been receiving ivermectin treatment since 2000 [11]. Both states are considered to be on track for disease elimination [2]. However, there is no evidence-based information on prevalence status or the infectivity status of blackflies at these sites in order to determine the transmission risk of onchocerciasis in first-line communities nearest to the waterfalls. The absence of data on onchocerciasis prevalence in these two regions, despite the observed blackfly activity, raises concerns about potential transmission dynamics, given the vector’s role in the epidemiology of the disease. This study was designed as an epidemiological survey to evaluate community knowledge, attitudes, and determine level of participation in ivermectin mass drug administration (MDA) in order to assess the onchocerciasis transmission risk in the region. As Nigeria transitions from control to elimination of onchocerciasis, this data will be vital for the Federal and State Ministries of Health, the National Onchocerciasis Elimination Committee (NOEC), and treatment implementing partners in developing targeted strategies to ensure optimal therapeutic coverage and achieve disease elimination.

Materials and methods

Ethics statement

The ethical approval for this study was granted by the Ethics Review Committees of the Osun State Ministry of Health (reference number OSHREC/PRS/569T/334) and the Ekiti State Ministry of Health (reference number MOH/EKHREC/EA/P/50). Written informed consent was first obtained from community leaders and religious heads of the communities. For participants aged 10 and below 18 years, recruitment was conducted with the written consent of their parents or guardians after explaining the study’s objectives in English and in the local language (Yoruba). Written informed consent was also obtained from participants above 18 years. All participants were informed that participation was voluntary and that they could withdraw at any point without any negative consequences to them. The research adhered to international ethical standards, including the 1964 Helsinki Declaration and its subsequent amendments.

Study area

This study was conducted between October and November 2024 in two first-line communities near the Arinta and Erin-Ijesha waterfalls. The first site, Erin-Ijesha (N7.569368, E4.891340), located in Oriade Local Government Area, Osun State, is the nearest community to the Erin-Ijesha waterfall. The second site, Ipole-Iloro (N7.586372, E4.936383), situated in Ekiti West Local Government Area, Ekiti State, is the first-line community to the Arinta waterfall. There is no documented information on the level of onchocerciasis endemicity in the LGAs where these communities are located. However, blackfly activity observed during a preliminary assessment of the waterfalls close to the communities prompted the selection of these locations for the study (Fig 1).

Fig 1. Map showing study locations and the waterfalls.

Fig 1

This map was created using primary data collected by the authors and developed in ArcGIS v10.8 software. Shapefiles for Nigeria, including boundary polygons and water bodies across all administrative levels, were sourced from publicly accessible databases available at Humanitarian Data Exchange, and are licensed under CC BY 4.0 (https://data.humdata.org/). No changes were made to the original shapefiles. The authors grant permission for the reuse of this map without restriction, provided appropriate credit is given to the source.

Study design and determination of sample size

This community-based cross-sectional study was conducted in two purposively selected first-line communities between October 2024 and November 2024. Local neglected tropical disease coordinators (LNTDs), facility health workers from the community primary health centers (PHCs), and local mobilizers facilitated community sensitization and mobilization efforts. Participants aged 10 years and above and who have been resident in the communities for 5 years and above were enrolled in the study. In the absence of prior data on prevalence and community knowledge of blackflies and onchocerciasis, Cochran’s formula; n = (Z^2 * P(1-P))/ E^2 was used to determine sample size. Where n = the required sample size, Z = the standard normal deviate, usually set at 1.96 for a 95% confidence level, P = the expected populations with knowledge of onchocerciasis in the population, which is usually assumed to be 0.5 (50%) in the absence of any previous record and E = the desired level of precision, which is usually set at 0.05 (5%) for most studies. The estimated sample size was 385.

Data collection and analysis

Following informed consent, four trained personnel administered the questionnaire with assistance from a local guide who translated the questions into the local language to ensure clarity and comprehension. The questionnaire comprised four sections: (i) socio-demographic information, (ii) knowledge of blackflies, (iii) knowledge of onchocerciasis, and (iv) attitudes and participation in mass ivermectin administration. Data were entered into Microsoft Excel and analyzed using the 2021 version of the Statistical Package for the Social Sciences (SPSS). Descriptive statistics were performed, and relationships between variables were assessed using t-tests and chi-square tests, with proportions analyzed at a 95% confidence interval.

Results

Socio-demographic characteristics of study participants

A total of 236 respondents from the two communities participated in the study, with 150 individuals from Erin-Ijesha and 86 from Ipole-Iloro. Female participants accounted for the majority (78.4%), while males constituted 21.6%. The largest age group represented was 61–80 years (44.1%) while the lowest age group represented were between the ages 10–20 (4.6%). Respondents with no formal education comprised the highest proportion (34.3%), whereas those with tertiary education were the least represented (7.7%) (Table 1).

Table 1. Socio-demographic characteristics of participants.

Variables No. of individuals at Erin-Ijesha (%) No. of individuals at Ipole-Iloro (%) Total number (%)
Number of participants 150 86 236
Age
 10–20 8 (5.3) 3 (3.5) 11 (4.6)
 21–40 32 (21.3) 4 (4.7) 36 (15.3)
 41–60 58 (38.7) 27 (31.4) 85 (36.0)
 61–80 52 (34.7) 52 (60.4) 104 (44.1)
Sex
 Male 31 (20.7) 20 (23.3) 51 (21.6)
 Female 119 (79.3) 66 (76.7) 185 (78.4)
Education
 Primary 34 (24.7) 35 (40.7) 69 (29.2)
 Secondary 55 (36.7) 13 (15.1) 68 (28.8)
 Tertiary 12 (8.0) 6 (7.0) 18 (7.7)
 No formal education 49 (32.6) 32 (37.2) 81 (34.3)
Occupation
 Student 10 (6.7) 3 (3.5) 13 (5.5)
 Farmer 33 (22.0) 41 (47.7) 74 (31.4)
 Trader 77 (51.3) 12 (14.0) 89 (37.7)
 Civil Servant 6 (4.0) 6 (6.9) 12 (5.1)
 Retired 15 (10.0) 10 (11.6) 25 (10.6)
 Unemployed 9 (6.0) 14 (16.3) 23 (9.7)

Knowledge on blackfly and bioecology of blackfly

Knowledge about blackflies varied among participants in the two communities. In Erin-Ijesha, 110 (73.3%) of respondents reported having heard of blackflies, while 40 (26.7%) had no knowledge. Additionally, 105 (70.0%) identified blackflies as a biting nuisance in the community, whereas 45 (30.0%) were unaware of this activity. In Ipole-Iloro, 72 (83.7%) of participants were familiar with blackflies, compared to 14 (16.3%) who have no knowledge. Furthermore, 70 (81.4%) confirmed the biting activity of blackflies in the community, while 16 (18.6%) lacked awareness. When prompted about the origin of blackflies, 81 (54.0%) of respondents in Erin-Ijesha attributed their presence to trees, 56 (37.3%) had no idea, and only 3 (2.0%) correctly identified rivers as their source. Similarly, in Ipole-Iloro, 63 (73.3%) believed blackflies originated from trees, 21 (24.4%) were unsure, and only 2 (2.3%) recognized rivers as their breeding sites. Occupation and their level of education were not found to have any significant influence on knowledge on bioecology of blackflies in the two communities (p > 0.05) (Table 2).

Table 2. Knowledge on blackflies and bioecology.

Questions Response Erin-Ijesha (%) Ipole-Iloro (%)
Have you heard of blackflies Yes 110 (73.3) 72 (83.7)
No 40 (26.7) 14 (16.3)
Do blackflies bite in your community? Yes 105 (70.0) 70 (81.4)
No 45 (30.0) 30 (34.9)
Where do these blackflies primarily come from? Trees 81 (54.0) 63 (73.3)
Rivers 3 (2.0) 2 (2.3)
Others 10 (6.7) 0 (0)
No idea 56 (37.3) 21 (24.4)
Which part of the body do blackflies mostly bite? Head 1 (0.7) 1 (1.2)
Hand 16 (10.7) 6 (6.9)
Legs 86 (57.3) 62 (72.1)
No idea 47 (31.3) 17 (19.8)
What are the immediate effects of a blackfly bite? Itching 97 (64.7) 66 (76.7)
Swelling 5 (3.3) 0 (0.0)
No idea 48 (32.0) 20 (23.3)
During which season do blackflies bite more frequently? Dry 69 (46.0) 46 (53.5)
Rainy 81 (54.0) 40 (46.5)
What time of day do blackflies usually bite? Day 75 (50.0) 63 (73.3)
Night 27 (18.0) 5 (5.8)
No idea 48 (32.0) 18 (20.9)
How do you prevent blackflies from biting you? Wearing socks 11 (7.3) 7 (8.1)
Clothings 68 (45.3) 37 (43.0)
Leaf extract 1 (0.7) 1 (1.2)
Ointments 8 (5.3) 6 (7.0)
Nothing 62 (41.3) 35 (40.7)

Knowledge on onchocerciasis

At Erin-Ijesha, 125 (83.3%) of respondents demonstrated knowledge and awareness of onchocerciasis, with 88.0% of the respondents accurately identifying the local name for the disease in their community. Similarly, at Ipole-Iloro, 74 (86.0%) of participants were familiar with the disease, and 75 (87.2%) of community members correctly recognized its local name. Despite high awareness levels of the disease, knowledge about the mode of transmission of onchocerciasis was notably poor in both communities. At Erin-Ijesha, 76.7% of respondents have no idea of the disease’s transmission route, while at Ipole-Iloro, 82.5% of the respondents also had no idea. Only 8.7% and 10.5% of respondents in Erin-Ijesha and Ipole-Iloro, respectively, correctly identified the blackfly as the vector responsible for the transmission. Misconceptions about the disease were prevalent, and knowledge of its common symptoms was limited. In Erin-Ijesha, 40.0% of respondents reported having no knowledge of the symptoms, while in Ipole-Iloro, this lack of knowledge was observed in 41.9% of the respondents (Table 3).

Table 3. Knowledge of participants on onchocerciasis.

Questions Response Erin-Ijesha (%) Ipole-Iloro (%)
Do you know what onchocerciasis is? Yes 125 (83.3) 74 (86.0)
No 25 (16.7) 12 (14.0)
What is the local name for onchocerciasis in your community? Sobia (Guinea worm) 0 (0.0) 0 (0.0)
Naarun (Onchocerciasis) 133 (88.7) 75 (87.2)
Arun fopawon (Soil-transmitted helminths) 0 (0.0) 0 (0.0)
No idea 17 (11.3) 11 (12.8)
How is the disease transmitted? Mosquito bite 1 (0.7) 3 (3.5)
Blackfly bite 13 (8.7) 9 (10.5)
Witchcraft 0 (0.0) 0 (0.0)
Hereditary 21 (14.0) 3 (3.5)
No idea 115 (76.7) 71 (82.5)
What are the common symptoms of onchocerciasis? Nodules 12 (8.0) 9 (10.5)
Leopard skin 70 (46.7) 18 (20.9)
Blindness/Loss of vision 8 (5.3) 23 (26.7)
No idea 60 (40.0) 36 (41.9)
Are you aware that this disease can lead to blindness if not treated? Yes 69 (46.0) 40 (46.5)
No 81 (54.0) 46 (53.5)

Attitude and level of participation in mass drug administration (MDA)

Awareness of ivermectin was high in both communities, with 127 (84.7%) in Erin-Ijesha and 73 (84.9%) in Ipole-Iloro having heard about the drug. Among those aware, 113 (75.3%) in Erin-Ijesha and 66 (77.6%) in Ipole-Iloro reported receiving at least one round of ivermectin. When asked about the total number of ivermectin rounds received, 23 (15.3%) of respondents in Erin-Ijesha reported receiving one round, 31 (20.7%) two rounds, 30 (20.0%) more than two rounds, and 29 (19.3%) more than five rounds. At Ipole-Iloro, 16 (24.2%) had received one round, 11 (16.7%) two rounds, 22 (33.3%) more than two rounds, and 17 (25.8%) more than five rounds. Among those 37 (24.7%) and 20 (23.3%) respondents in Erin-Ijesha and Ipole-Iloro respectively who had not received ivermectin, 11 (29.7%) in Erin-Ijesha and 8 (40.0%) in Ipole-Iloro cited refusal as the reason, while 10 (27.0%) and 9 (45.0%), respectively, reported unawareness of the drug distribution. Regarding willingness to participate in future ivermectin campaigns, 97 (64.7%) of respondents in Erin-Ijesha and 55 (64.0%) in Ipole-Iloro expressed willingness, whereas 53 (35.3%) and 31 (36.0%) respectively, declined.

In Erin-Ijesha, 74 (49.3%) respondents reported being aware of community sensitization efforts on onchocerciasis, while 76 (50.7%) indicated a lack of awareness. Similarly, at Ipole-Iloro, 47 (54.7%) were aware of such efforts, while 39 (45.3%) were not. When asked if sensitization efforts on onchocerciasis elimination could be improved, 116 (77.3%) in Erin-Ijesha and 77 (89.5%) in Ipole-Iloro responded affirmatively. Regarding suggestions for improvement in sensitization efforts in Erin-Ijesha, 44 (29.3%) recommended increased health worker outreach, while 12 (8.0%) suggested leveraging radio, TV, and social media campaigns. In Ipole-Iloro, 13 (15.1%) similarly advocated for more health worker outreach, and 13 (15.1%) also supported the use of radio, TV, and social media for sensitization campaigns. In Erin-Ijesha, education level was found to significantly influenced willingness to participate in future mass administration of ivermectin (p = 0.00). Additionally, significant association was also observed between educational level and willingness to participate in future mass administration of ivermectin in Ipole-Iloro (p = 0.04). (Table 4).

Table 4. Attitude and level of participation in mass drug administration (MDA).

Questions Response Erin-Ijesha (%) Ipole-Iloro (%)
Have you heard about ivermectin or Mectizan before? Yes 127 (84.7) 73 (84.9)
No 23 (15.3) 13 (15.1)
Have you ever received ivermectin before? Yes 113 (75.3) 66 (76.7)
No 37 (24.7) 20 (23.3)
If Yes, how many rounds? once 23 (15.3) 16 (24.2)
Twice 31 (20.7) 11 (16.7)
> 2 times 30 (20.0) 22 (33.3)
> 5 times 29 (19.3) 17 (25.8)
If you have not received treatment, what is the reason? Not aware of distribution 10 (27.0) 9 (45.0)
I just refuse 11 (29.7) 8 (40.0)
Not always around 4 (10.8) 2 (10.0)
Others 12 (32.4) 1 (5.0)
Do you know of any local medication or treatment for onchocerciasis? Yes 36 (24.0) 14 (16.3)
No 114 (76.0) 72 (83.7)
Are you aware of any community sensitization efforts regarding onchocerciasis? Yes 74 (49.3) 47 (54.7)
No 76 (50.7) 39 (45.3)
Do you believe efforts to sensitize the community about onchocerciasis elimination can be improved? Yes 116 (77.3) 77 (89.5)
No 4 (2.7) 1 (1.2)
Unsure 30 (20.0) 8 (9.3)
What would help increase awareness and uptake of ivermectin? More health worker outreach 44 (29.3) 13 (15.1)
Radio/TV/social media campaigns 12 (8.0) 13 (15.1)
Educational sessions in schools 10 (6.7) 4 (4.7)
Others 24 (16.0) 7 (8.1)
No response 60 (40.0) 49 (56.9)
Have you noticed any stigma or discrimination toward those who show symptoms of onchocerciasis in your community? Yes 6 (4.0) 0 (0.0)
No 144 (96.0) 86 (100)
Would you be willing to participate in future MDA for onchocerciasis? Yes 97 (64.7) 55 (64.0)
No 53 (35.3) 31 (36.0)

Discussion

This study was carried out in the study communities based on outcome of a preliminary breeding site assessment of rivers in Southwest Nigeria that revealed the biting activity of blackflies at the Erin-Ijesha and Arinta waterfall. The high biting density observed at the waterfalls necessitated the need to conduct a knowledge, attitude and practice of community members with regards to blackfly and its ecology, onchocerciasis and level of participation in treatment programs in first-line communities close to the waterfalls to determine the transmission risk of onchocerciasis in the communities.

Majority of participants in both communities demonstrated awareness of blackflies with most acknowledging the biting nuisance they cause. However, despite this impressive knowledge, the majority lacked an understanding of the bioecology of blackflies. Misconceptions were widespread, with only 2.0% of respondents in Erin-Ijesha and 2.3% in Ipole-Iloro correctly identifying that blackflies breed in fast-flowing rivers, while the majority believed that the flies originate from trees. This misunderstanding aligns with previously documented misconceptions [1214]. The lack of knowledge about blackfly bioecology among residents in endemic communities may stem from onchocerciasis control efforts historically focusing on parasite through mass drug administration, with little to non-existent vector control implementation in these communities. This poor knowledge could inadvertently increase exposure to blackfly bites, thereby further increasing transmission risk of onchocerciasis in these communities.

There were variations in participants’ knowledge of seasonal blackfly biting activity across the study communities. In Erin-Ijesha, 54% of participants reported that blackflies bite more during the wet season while in Ipole-Iloro, 53.5% believed biting intensity is higher in the dry season. This contrasts with other studies, such as [13] where most participants associated higher biting frequency with the wet season. These variations may stem from regional differences in vector dynamics. Some studies have reported greater blackfly densities during dry season than wet season [15,16], attributed to ecological and climatic factors specific to different Simulium species in different ecological zones. Majority of the respondents identified itching as an immediate effect of blackfly bites. This after-effect occurs when the flies inject saliva containing irritant compounds from the epidermal to the dermal layer of the skin, triggering histamine receptors and causing itching along with other skin responses [14,17]. In response to the painful bites of blackflies, most respondents reported using protective measures such as wearing clothing, socks, and applying ointments. These practices align with findings from previous studies conducted across Africa [4,13,18]. Adeleke et al. [12] also documented the use of chemical mixtures, including diesel oil, palm oil, kerosene, and leaf extracts, as repellents. While effective, some of these substances pose health risks when applied to the skin or inhaled during application, potentially causing severe headaches, respiratory difficulties, skin irritation, or burns [14]. Although many take precautionary measures against the flies, a significant proportion of respondents, 41.3% in Erin-Ijesha and 40.7% in Ipole-Iloro reported taking no measures to prevent bites. This lack of protective behaviour leaves a substantial number of the population exposed to bites, thereby increasing the risk of onchocerciasis transmission within these communities.

It is noteworthy that the majority of participants demonstrated awareness of onchocerciasis and correctly identified its local name, “naarun.” Similar patterns of knowledge have been observed in other studies, where most respondents recognized the disease and provided its local name [19,20]. This basic knowledge is likely attributable to the mass drug administration (MDA) campaigns with ivermectin, which have been ongoing in these communities for over two decades. However, despite this encouraging disease awareness, most participants, 76.7% in Erin-Ijesha and 82.5% in Ipole-Iloro were unaware of how onchocerciasis is transmitted. Only 8.7% and 10.5% in Erin-Ijesha and Ipole-Iloro, respectively, associated the disease with blackfly bites. This limited knowledge of the vector is a reflection of the insufficient community sensitization and education efforts by the community drug distributors (CDDs). This low knowledge can contribute to increased transmission risk as individuals are less likely to take preventive measures when unaware of the risks posed by blackfly exposure. Additionally, many participants reported no knowledge of the disease’s symptoms or its potential to cause blindness. Comparable findings have been documented in other southern regions of Nigeria, where study participants failed to link the ocular symptoms of onchocerciasis to blackfly bites [1921]. The lack of knowledge of these late-stage manifestations could potentially impact drug acceptability and uptake, thereby further increasing transmission risk. These findings further indicate shortfall in community health education and sensitization by CDDs during mass drug administration campaigns.

A notable finding from this study is the high percentage of individuals in both communities who were aware of and had received ivermectin. Majority of participants were aware of ivermectin with 75.3% in Erin-Ijesha and 76.7% in Ipole-Iloro reporting they had received at least one round of treatment. A possible explanation for the high uptake of ivermectin despite low knowledge of onchocerciasis could be due to the familiarity of community members with the CDDs, who are often known members of the community. This familiarity likely encourages ivermectin uptake, further emphasizing the effectiveness of engaging community members as CDDs. Additionally, many respondents claimed ivermectin also treats intestinal infections. This aligns with findings previously reported in Ethiopia [4]. Among those who had not participated in the treatment programs, many were persistent drug refusers, citing no specific reasons for rejecting the medication. Majority of these people who simply refuse the medicine in both communities had no formal education, further highlighting the importance of education on treatment uptake. Others were either unaware of the distribution efforts or unavailable during the campaigns. These findings suggest that community drug distributors rarely follow up with individuals who miss treatment, limiting both treatment uptake and therapeutic coverage. Similar observations were reported by [20] where individuals excluded were not often revisited, hindering efforts to achieve inclusive coverage. These untreated individuals, who remain as exposed to blackfly bites as those on ivermectin, may act as reservoir hosts and a source of re-infection of onchocerciasis within these communities [22]. The limited understanding of the disease’s symptoms contributes to inappropriate alternative treatment-seeking behaviours [23]. Some of the participants claimed to take local herbs for the treatment of onchocerciasis. This is similar to what was reported in Southern Nigeria [20]. Conversely, improved awareness is associated with better prevention measures, adherence to treatment, and reduced economic burden [20]. There was no significant relationship between knowledge of onchocerciasis and ivermectin uptake in either community (p > 0.05).

The lack of adequate sensitization again became evident when participants were asked about their willingness to engage in future mass drug administration programs. Only 64% in Erin-Ijesha and 64.7% in Ipole-Iloro expressed a willingness to participate. However, education was found to significantly influence this decision in both communities, with higher levels of education correlating with greater acceptance of ivermectin treatment (p < 0.05). This further highlights the importance of education in improving treatment acceptance, suggesting that more health education in schools, targeted health workers outreach and media sensitization could significantly improve acceptability and uptake of ivermectin in endemic communities.

Conclusion

The study reveals limited knowledge of blackfly bioecology, onchocerciasis, and its public health implications among residents of both first-line communities. This knowledge gap poses a significant challenge to ongoing control efforts and may hinder progress toward disease elimination. Given the high-risk status of these communities due to proximity to active breeding sites, it is important for federal and state health ministries and their treatment implementing partners, to prioritize targeted interventions. Improving sensitization campaigns and enhancing community awareness are crucial steps toward increasing treatment uptake, with a view to reducing the transmission risk of onchocerciasis and accelerating progress toward disease elimination

Supporting information

S1 File. Structured Questionnaire used for the survey of knowledge, practices and level of participation in mass drug administration at Erin-Ijesha and Ipole-Iloro communities in Southwest, Nigeria.

(DOCX)

pntd.0013411.s001.docx (203.6KB, docx)
S2 File. Response used for the determination of knowledge, practices and level of participation in mass drug administration at Erin-Ijesha and Ipole-Iloro communities in Southwest, Nigeria.

(XLSX)

pntd.0013411.s002.xlsx (51.3KB, xlsx)

Acknowledgments

The authors wish to acknowledge the support of the community leaders of Erin-Ijesha and Ipole-Iloro community for their support. We would also like to appreciate the state neglected tropical diseases (NTD) coordinators, local NTD coordinators and local mobilizers for their support towards ensuring the success of this study.

Data Availability

All data generated and/or analysed during this study is uploaded as Supporting information.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.WHO. Onchocerciasis (river blindness). WHO. https://www.who.int/news-room/fact-sheets/detail/onchocerciasis. 2022. [Google Scholar]
  • 2.Federal Ministry of Health FM. Nigeria onchocerciasis elimination plan. Abuja: FMoH. 2017. https://www.cartercenter.org/resources/pdfs/news/health_publications/river_blindness/nigeria-onchocerciasis-elimination-plan-feb2017.pdf [Google Scholar]
  • 3.Nwoke BEB, Akpan NM, Cama V, Ekpo UF, Idyorough AE, Mafe MA, et al. Onchocerciasis in Nigeria 1: history of control efforts. Niger J Parasitol. 2023;44:1–10. [Google Scholar]
  • 4.Weldegebreal F, Medhin G, Weldegebriel Z, Legesse M. Assessment of community’s knowledge, attitude and practice about onchocerciasis and community directed treatment with Ivermectin in Quara District, north western Ethiopia. Parasit Vectors. 2014;7:98. doi: 10.1186/1756-3305-7-98 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Frallonardo L, Di Gennaro F, Panico GG, Novara R, Pallara E, Cotugno S, et al. Onchocerciasis: Current knowledge and future goals. Front Trop Dis. 2022;3. doi: 10.3389/fitd.2022.986884 [DOI] [Google Scholar]
  • 6.Lakwo T, Oguttu D, Ukety T, Post R, Bakajika D. Onchocerciasis Elimination: Progress and Challenges. Res Rep Trop Med. 2020;11:81–95. doi: 10.2147/RRTM.S224364 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009;3(7):e497. doi: 10.1371/journal.pntd.0000497 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors. 2012;5:28. doi: 10.1186/1756-3305-5-28 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012;6(9):e1825. doi: 10.1371/journal.pntd.0001825 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.World Health Organization. Elimination of human onchocerciasis: progress report, 2023–2024. Wkly Epidemiol Rec. 2024;99(41):577–90. [Google Scholar]
  • 11.Ojurongbe O, Akindele AA, Adeleke MA, Oyedeji MO, Adedokun SA, Ojo JF, et al. Co-endemicity of loiasis and onchocerciasis in rain forest communities in southwestern Nigeria. PLoS Negl Trop Dis. 2015;9(3):e0003633. doi: 10.1371/journal.pntd.0003633 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Adeleke M, Sam-Wobo SO, Mafiana C, Olatunde GO. Perception on bioecology of onchocerciasis vectors around Osun River, South-western Nigeria. J Public Health Epidemiol. 2011;3(4):162–6. [Google Scholar]
  • 13.Busari LO, Adeleke MA, Surakat OA, Akindele AA, Fasasi KA, Ojurongbe O. Black flies and Onchocerciasis: Knowledge, attitude and practices among inhabitants of Alabameta, Osun State, Southwestern, Nigeria. PLoS Negl Trop Dis. 2022;16(4):e0010320. doi: 10.1371/journal.pntd.0010320 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Domche A, Nana-Djeunga HC, Yemeli LD, Nanga CL, Boussinesq M, Njiokou F, et al. Knowledge/perception and attitude/practices of populations of two first-line communities of the Centre Region of Cameroon regarding onchocerciasis and black fly nuisance and bio-ecology. Parasit Vectors. 2021;14(1):546. doi: 10.1186/s13071-021-05048-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Eyo JE, Ikechukwu EO, Ubachukwu PO, Ivoke N, Ekeh FN. Effects of climatic conditions on the biting density and relative abundance of Simulium damnosum complex in a rural Nigerian farm settlement. Ann Agric Environ Med. 2014;21(4):697–700. doi: 10.5604/12321966.1129917 [DOI] [PubMed] [Google Scholar]
  • 16.Otabil KB, Gyasi SF, Awuah E, Obeng-Ofori D, Tenkorang SB, Kessie JA, et al. Biting rates and relative abundance of Simulium flies under different climatic conditions in an onchocerciasis endemic community in Ghana. Parasit Vectors. 2020;13(1):229. doi: 10.1186/s13071-020-04102-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Thomsen JS, Sonne M, Benfeldt E, Jensen SB, Serup J, Menné T. Experimental itch in sodium lauryl sulphate-inflamed and normal skin in humans: a randomized, double-blind, placebo-controlled study of histamine and other inducers of itch. Br J Dermatol. 2002;146(5):792–800. doi: 10.1046/j.1365-2133.2002.04722.x [DOI] [PubMed] [Google Scholar]
  • 18.Yirga D, Hajito K, Wondafrash M, Kassahun W, Deribe K. Knowledge and belief about cause and prevention of onchocerciasis in Bebeka, Southwest Ethiopia. Ethiop J Health Sci. 2008;18:1–7. [Google Scholar]
  • 19.Adeoye AO, Ashaye AO, Onakpoya OH. Perception and attitude of people toward onchocerciasis (river blindness) in South Western Nigeria. Middle East Afr J Ophthalmol. 2010;17(4):310–4. doi: 10.4103/0974-9233.71594 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Surakat OA, Sam-Wobo SO, Ademolu KO, Adekunle MF, Adekunle ON, Monsuru AA, et al. Assessment of community knowledge and participation in onchocerciasis programme, challenges in ivermectin drug delivery, distribution and non-compliance in Ogun State, southwest Nigeria. Infect Dis Health. 2018;23(3):137–45. doi: 10.1016/j.idh.2018.03.001 [DOI] [PubMed] [Google Scholar]
  • 21.Afolabi O, Okaka C, Oke I, Oniya M. Knowledge, Attitude and Perception of Onchocerciasis and Ivermectin Treatment in Idogun Community, Ondo State, Nigeria. BJMMR. 2016;13(4):1–7. doi: 10.9734/bjmmr/2016/23566 [DOI] [Google Scholar]
  • 22.Brieger WR, Okeibunor JC, Abiose AO, Wanji S, Elhassan E, Ndyomugyenyi R, et al. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Parasit Vectors. 2011;4:152. doi: 10.1186/1756-3305-4-152 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Nwoke BE, Onwuliri CO, Ufomadu GO. Onchocerciasis in Plateau State; Nigeria: ecological background, local disease perception & treatment; and vector/parasite dynamics. J Hyg Epidemiol Microbiol Immunol. 1992;36(2):153–60. [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0013411.r001

Decision Letter 0

Peter Fischer

6 Mar 2025

Knowledge and attitude on blackflies and onchocerciasis and participation in Mass Drug Administration in frontline communities near Erin-Ijesha and Arinta waterfalls, Southwest Nigeria.

PLOS Neglected Tropical Diseases

Dear Dr. Dauda,

Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The editor agrees with one reviewer that the study as it is written now, is mostly of local interest. Therefore it is important to point out in a substantially revised version why the results are important for the national onchocerciasis elimination program in Nigeria and elsewhere in Africa.

Please submit your revised manuscript within 60 days May 05 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Peter U Fischer

Academic Editor

PLOS Neglected Tropical Diseases

Nigel Beebe

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

Journal Requirements:

1) Please ensure that the CRediT author contributions listed for every co-author are completed accurately and in full.

At this stage, the following Authors/Authors require contributions: Glory Blessing Jokanola. Please ensure that the full contributions of each author are acknowledged in the "Add/Edit/Remove Authors" section of our submission form.

The list of CRediT author contributions may be found here: https://journals.plos.org/plosntds/s/authorship#loc-author-contributions

2) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines: 

https://journals.plos.org/plosntds/s/figures

3) Some material included in your submission may be copyrighted. According to PLOSu2019s copyright policy, authors who use figures or other material (e.g., graphics, clipart, maps) from another author or copyright holder must demonstrate or obtain permission to publish this material under the Creative Commons Attribution 4.0 International (CC BY 4.0) License used by PLOS journals. Please closely review the details of PLOSu2019s copyright requirements here: PLOS Licenses and Copyright. If you need to request permissions from a copyright holder, you may use PLOS's Copyright Content Permission form.

Please respond directly to this email and provide any known details concerning your material's license terms and permissions required for reuse, even if you have not yet obtained copyright permissions or are unsure of your material's copyright compatibility. Once you have responded and addressed all other outstanding technical requirements, you may resubmit your manuscript within Editorial Manager. 

Potential Copyright Issues:

- Figure 1. Please provide a direct link to the base layer of the map (i.e., the country or region border shape) and ensure this is also included in the figure legend; and provide a link to the terms of use / license information for the base layer image or shapefile. We cannot publish proprietary or copyrighted maps (e.g. Google Maps, Mapquest) and the terms of use for your map base layer must be compatible with our CC BY 4.0 license.

Note: if you created the map in a software program like R or ArcGIS, please locate and indicate the source of the basemap shapefile onto which data has been plotted.

If your map was obtained from a copyrighted source please amend the figure so that the base map used is from an openly available source. Alternatively, please provide explicit written permission from the copyright holder granting you the right to publish the material under our CC BY 4.0 license.

If you are unsure whether you can use a map or not, please do reach out and we will be able to help you. The following websites are good examples of where you can source open access or public domain maps:

* U.S. Geological Survey (USGS) - All maps are in the public domain. (http://www.usgs.gov)

* PlaniGlobe - All maps are published under a Creative Commons license so please cite u201cPlaniGlobe, http://www.planiglobe.com, CC BY 2.0u201d in the image credit after the caption. (http://www.planiglobe.com/?lang=enl)

* Natural Earth - All maps are public domain. (http://www.naturalearthdata.com/about/terms-of-use/).

4) In the online submission form, you indicated that "All data generated and/or analysed during this study will be made available by the corresponding author upon reasonable request". All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either

- In a public repository

- Within the manuscript itself

- Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues.

Reviewers' Comments:

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods:

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: (No Response)

Reviewer #2: -The broader methodology used in the study to achieve the objective are adequate. However, authors need to provide additional information around the population used for sample size calculation as well as information on the endemicity status of the LGA of the study communities.

Reviewer #3: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? Yes

-Is the study design appropriate to address the stated objectives? yes

-Is the population clearly described and appropriate for the hypothesis being tested? not clear how the study participants were selected. Not representative of the general population

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? yes

-Were correct statistical analysis used to support conclusions? limited statistical analysis done

-Are there concerns about ethical or regulatory requirements being met? No

Results:

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

Reviewer #2: The analysis and data presentation in the current study are adequate.

Reviewer #3: -Does the analysis presented match the analysis plan? No analysis plan

-Are the results clearly and completely presented? Yes

-Are the figures (Tables, Images) of sufficient quality for clarity? Not very good

Conclusions:

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: (No Response)

Reviewer #2: While the conclusions is largely supported by data presented, authors need to clarify, modify and delete some conclusion presented in the study as data presented in the study are inadequate to infer such conclusion. Conclusion should be within the limit of data presented and limitations of study should be included.

Reviewer #3: -Are the conclusions supported by the data presented? ok

-Are the limitations of analysis clearly described? Not described

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? data are mainly of local importance

-Is public health relevance addressed? Yes

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: "Comunities not previously mapped." What does this mean?

The study population was not representative of the general pululation. > 70% women, and young people underrepresented

Limited number of farmers generally most exposed to blackfly biting

No study limitations are mentioned

No recommendations are proposed to further investigate the onchocerciasis endemicity in the area?

Improving health education seems to be the only recommendation

No qualitative research done

No CDTI coverage data reported by CDDs?

Summary and General Comments:

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: (No Response)

Reviewer #2: This is generally a well done study. However, authors should address all the critical comments in the manuscript to ensure the interpretation of data and information generated from the study is not over-extended beyond what is necessary.

Reviewer #3: Results of the study are mainly of local importance

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes:  Robert Colebunders

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Figure resubmission:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions.

Reproducibility:

?>

Attachment

Submitted filename: Reviewer comment - PLOS NTD - 01.28.2025.docx

pntd.0013411.s003.docx (15.6KB, docx)
Attachment

Submitted filename: PNTD-D-24-01867_reviewer.pdf

pntd.0013411.s004.pdf (1.2MB, pdf)
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0013411.r003

Decision Letter 1

Peter Fischer

12 Jun 2025

Knowledge and attitude of populations on blackflies and onchocerciasis and participation in Mass Drug Administration in first-line communities near Erin-Ijesha and Arinta waterfalls, Southwest Nigeria.

PLOS Neglected Tropical Diseases

Dear Dr. Dauda,

Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript within 60 days Jul 12 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Peter U Fischer

Academic Editor

PLOS Neglected Tropical Diseases

Nigel Beebe

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

Additional Editor Comments (if provided):

The authors addressed most of the reviewers’ comments. However, the editor has still some concerns about this ms.

Line 82/83 Reference 10 clearly states that the reported population treated in Nigeria in 2023 was 34.9 million. What do the authors mean with ‘Currently, ivermectin has been administered to over 45 million Nigerians…’? [10]

Table 1. What do the authors mean with ‘Numbers’? Number of study participants?

Table 3: Onchodermatitis and itching are the most common signs of onchocerciasis. Why was this not included? How is ‘ocular dermatitis’ defined? Do the authors mean periorbital dermatitis? Ocular disease caused by O. volvulus that can be easily seen is sclerosing ceratitis. How would this be included in the table. How is blindness defined?

Line 199. Why did the authors introduce the phrase mass administration of medicine (MAM)? What is the difference to the commonly used term mass drug administration (MDA)?

Table 4. CDTi is a special form of MDA. What is the difference between CDTi and MAM?

Line 331. Why is knowledge of blackfly bioecology important to increase compliance to MDA? Many studies have shown that trust to community drug distributors is more important than disease specific knowledge. The authors may want to address this point more in detail in their discussion.

In addition, the ms still contains typos (for example Table 2 blackflies vs black flies).

Journal Requirements:

1) Some material included in your submission may be copyrighted. According to PLOSu2019s copyright policy, authors who use figures or other material (e.g., graphics, clipart, maps) from another author or copyright holder must demonstrate or obtain permission to publish this material under the Creative Commons Attribution 4.0 International (CC BY 4.0) License used by PLOS journals. Please closely review the details of PLOSu2019s copyright requirements here: PLOS Licenses and Copyright. If you need to request permissions from a copyright holder, you may use PLOS's Copyright Content Permission form.

Please respond directly to this email and provide any known details concerning your material's license terms and permissions required for reuse, even if you have not yet obtained copyright permissions or are unsure of your material's copyright compatibility. Once you have responded and addressed all other outstanding technical requirements, you may resubmit your manuscript within Editorial Manager. 

Potential Copyright Issues:

i)Figure 1. Thank you for including this link: https://www.hydrosheds.org/products/hydrorivers . However, it does not comply with PLOS CC:BY 4.0 requirements.

Please (a) provide a direct link to the base layer of the map (i.e., the country or region border shape) and ensure this is also included in the figure legend; and (b) provide a link to the terms of use / license information for the base layer image or shapefile. We cannot publish proprietary or copyrighted maps (e.g. Google Maps, Mapquest) and the terms of use for your map base layer must be compatible with our CC BY 4.0 license.

Note: if you created the map in a software program like R or ArcGIS, please locate and indicate the source of the basemap shapefile onto which data has been plotted.

If your map was obtained from a copyrighted source please amend the figure so that the base map used is from an openly available source. Alternatively, please provide explicit written permission from the copyright holder granting you the right to publish the material under our CC BY 4.0 license.

If you are unsure whether you can use a map or not, please do reach out and we will be able to help you. The following websites are good examples of where you can source open access or public domain maps:

* U.S. Geological Survey (USGS) - All maps are in the public domain. (http://www.usgs.gov)

* PlaniGlobe - All maps are published under a Creative Commons license so please cite u201cPlaniGlobe, http://www.planiglobe.com, CC BY 2.0u201d in the image credit after the caption. (http://www.planiglobe.com/?lang=enl)

* Natural Earth - All maps are public domain. (http://www.naturalearthdata.com/about/terms-of-use/).

2) We note that your Data Availability Statement is currently as follows: "All data generated and/or analysed during this study is uploaded as supplementary information.". Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data: 

1) The values behind the means, standard deviations and other measures reported;

2) The values used to build graphs;

3) The points extracted from images for analysis..

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. 

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

Reviewers' Comments:

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Figure resubmission:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions.

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0013411.r005

Decision Letter 2

Nigel Beebe

31 Jul 2025

Dear Mr Dauda,

We are pleased to inform you that your manuscript 'Knowledge and attitude of populations on blackflies and onchocerciasis and participation in Mass Drug Administration in first-line communities near Erin-Ijesha and Arinta waterfalls, Southwest Nigeria.' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Nigel Beebe, PhD

Section Editor

PLOS Neglected Tropical Diseases

Nigel Beebe

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

***********************************************************

Thanks for attending to the reviewer's comments.

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0013411.r006

Acceptance letter

Nigel Beebe

Dear Mr Dauda,

We are delighted to inform you that your manuscript, "Knowledge and attitude of populations on blackflies and onchocerciasis and participation in Mass Drug Administration in first-line communities near Erin-Ijesha and Arinta waterfalls, Southwest Nigeria.," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Structured Questionnaire used for the survey of knowledge, practices and level of participation in mass drug administration at Erin-Ijesha and Ipole-Iloro communities in Southwest, Nigeria.

    (DOCX)

    pntd.0013411.s001.docx (203.6KB, docx)
    S2 File. Response used for the determination of knowledge, practices and level of participation in mass drug administration at Erin-Ijesha and Ipole-Iloro communities in Southwest, Nigeria.

    (XLSX)

    pntd.0013411.s002.xlsx (51.3KB, xlsx)
    Attachment

    Submitted filename: Reviewer comment - PLOS NTD - 01.28.2025.docx

    pntd.0013411.s003.docx (15.6KB, docx)
    Attachment

    Submitted filename: PNTD-D-24-01867_reviewer.pdf

    pntd.0013411.s004.pdf (1.2MB, pdf)
    Attachment

    Submitted filename: Rebuttal letter.docx

    pntd.0013411.s006.docx (27.4KB, docx)
    Attachment

    Submitted filename: Rebuttal_letter_auresp_2.docx

    pntd.0013411.s007.docx (19.7KB, docx)

    Data Availability Statement

    All data generated and/or analysed during this study is uploaded as Supporting information.


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES